Navigation Links
Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement with Teva
Date:4/26/2012

PITTSBURGH and NEW YORK, April 26, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) and Pfizer Inc. (NYSE: PFE) today announced that Meridian Medical Technologies, a Pfizer subsidiary, has entered into a settlement agreement with Teva that will resolve pending patent litigation related to its abbreviated new drug application (ANDA) for a generic epinephrine auto-injector.

According to the terms of the settlement, Teva may launch a generic epinephrine auto-injector covered by its ANDA on June 22, 2015 or earlier under certain circumstances, subject to receipt of approval from the U.S. Food and Drug Administration. Teva currently does not have tentative approval from the FDA for its epinephrine auto-injector product.

Meridian manufactures EpiPen® Auto-Injector and Mylan Specialty markets and distributes the product in the United States.

Additional terms of the agreement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission.

About Mylan
Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com.

Pfizer Inc: Working together for a healthier world®
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Launches Generic Version of Zyprexa® Tablets
2. Mylan Launches First Generic Version of Lescol® Capsules
3. Mylan Schedules First Quarter 2012 Financial Results Conference Call and Live Webcast
4. Mylan One of First to Launch Generic Version of Boniva®
5. Mylan Canada Receives Health Canada Approval for Generic Version of Crestor®
6. Mylan Continues to Pursue Damages and Injunction Against Sunovions Brovana® in Ongoing Litigation
7. Mylan Pharmaceuticals President Tony Mauro Elected Chairman of GPhA
8. Mylan Secures an Additional $300 Million of Committed Financing
9. Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year
10. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement
11. Mylan to Change Name of Specialty Subsidiary From Dey Pharma to Mylan Specialty
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016 TapImmune,Inc. ... of innovative peptide and gene-based immunotherapeutics and vaccines for the ... be presenting at the 3rd Annual Growth Capital Expo ... th , 2016 at Caesars Palace in Las Vegas, Nevada.  ... on Wednesday, May 4 th by Dr. John ...
(Date:4/27/2016)...   , Total ... Consumable Sales  Clinical sales grow 16% year-over-year  ... MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal ... first quarter ended March 31, 2016 and provided an ... commercial strategy. First Quarter 2016 Revenue Results ...
(Date:4/27/2016)... SHAWNEE, Kan. , April 27, 2016 /PRNewswire/ ... Martabano , a senior from the University of ... winner of the Bayer Excellence in Communication Award ... veterinary schools, which were awarded a total of ... Over the last four years, Bayer has provided ...
Breaking Medicine Technology:
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... On Tuesday, ... hospitals across the Southeast, celebrated the signature of Gov. Nathan Deal on SB 258, ... Geoff Duncan (R - Cumming), offers a 70% tax credit to individuals and corporations ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House ... their loans, more information about their loan terms and accounts, and more protections ... debt, including federal and private loans, has reached $1.3 trillion, with 43 million ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... that infants born with severe congenital diaphragmatic hernia have better survival rates if ... congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails to form completely, letting ...
(Date:4/29/2016)... ... April 29, 2016 , ... Mobility Designed is ... pressure on the armpits, the M+D Crutch evenly distributes body weight from the elbow ... and hands when using the crutches than with other crutches. , Co-founders Max and ...
(Date:4/29/2016)... Tarzana, CA (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type ... is to blame for the majority of skin cancer deaths. More than 10,000 people are ... average age at diagnosis is 62, it is the one of the most commonly diagnosed ...
Breaking Medicine News(10 mins):